NCT06744686View on ClinicalTrials.gov

Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

March 12, 2024

Study Completion Date

June 18, 2024

Conditions

Chronic Hepatitis B

Interventions

DRUG

HT-102

50mg, 150mg, 300mg, 600mg

DRUG

HT-102

50mg, 150mg, 300mg

DRUG

Placebo

Trial Locations (7)

200080

Shanghai General Hospital, Shanghai

250102

Shandong Public Health Clinical Center, Jinan

325035

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

350025

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

450015

The Sixth People's Hospital of Zhengzhou, Zhengzhou

471000

Luoyang Central Hospital, Luoyang

511518

People's Hospital of Qingyuan, Qingyuan

All Listed Sponsors

lead

Suzhou HepaThera Biotech Co., Ltd.

INDUSTRY

NCT06744686 - Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection) | Biotech Hunter | Biotech Hunter